A comprehensive review on recent approaches for cancer drug discovery associated with artificial intelligence

Comput Biol Med. 2022 Nov:150:106140. doi: 10.1016/j.compbiomed.2022.106140. Epub 2022 Sep 22.

Abstract

Through the revolutionization of artificial intelligence (AI) technologies in clinical research, significant improvement is observed in diagnosis of cancer. Utilization of these AI technologies, such as machine and deep learning, is imperative for the discovery of novel anticancer drugs and improves existing/ongoing cancer therapeutics. However, building a model for complicated cancers and their types remains a challenge due to lack of effective therapeutics that hinder the establishment of effective computational tools. In this review, we exploit recent approaches and state-of-the-art in implementing AI methods for anticancer drug discovery, and discussed how advances in these applications need to be considered in the current cancer therapeutics. Considering the immense potential of AI, we explore molecular docking and their interactions to recognize metabolic activities that support drug design. Finally, we highlight corresponding strategies in applying machine and deep learning methods to various types of cancer with their pros and cons.

Keywords: Artificial intelligence; Drug discovery; Machine learning; Molecular docking.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Artificial Intelligence
  • Drug Discovery / methods
  • Humans
  • Machine Learning
  • Molecular Docking Simulation
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents